

# **TARGETED TEMPERATURE MANAGEMENT AFTER CARDIAC ARREST: SAVING THE NEURONS**

**MARY ANN BAUTISTA, DNP, RN, AGCNS-BC, AGACNP-BC**

## DISCLOSURE

#### Financial Support: Attune Medical

## **COURSE OBJECTIVES**

1. Review the mechanisms of injury after cardiac arrest.
2. Review how Targeted Temperature Management (TTM) mitigates injuries after cardiac arrest.
3. Discuss the stages of TTM.
4. Discuss shivering and prevention strategies.

## STATISTICS

- Cardiac arrest 3<sup>rd</sup> leading cause of death in the US.
- 395,000 out-of-hospital cardiac arrests (OHCAs) /year
- 200,000 in-hospital cardiac arrests/year
- Survival rate for OHCAs = 7.6%

---



---



---



---



---



---




---



---

## POST- CARDIAC ARREST CARE



Google images, 2018

---



---



---



---



---



---



---



---

## DEFINITION

Targeted Temperature Management (TTM):

- induced hypothermia
- active control of temperature at any target




---



---



---



---



---



---



---



---

## GOALS OF TTM

- Temper the post- cardiac arrest inflammatory cascade
- To reduce cerebral oxygen consumption, blood flow and edema
- Improve oxygen supply and demand mismatch
- Improve neurologic outcomes

---



---



---



---



---



---



---



---



---

## MECHANISMS OF INJURY POST- CARDIAC ARREST



Google Images 2018

---



---



---



---



---



---



---



---



---

## POST-CARDIAC ARREST BRAIN INJURY




---



---



---



---



---



---



---



---



---

## MYOCARDIAL DYSFUNCTION

- LV dysfunction
- Myocardial stunning
- Cardiogenic shock

---



---



---



---



---



---




---



---

## MECHANISMS OF INJURY AFTER CARDIAC ARREST: ISCHEMIA




---



---



---



---



---



---




---



---

## REPERFUSION INJURY WITH ROSC




---



---



---



---



---



---



---



---

## PERSISTENT PRECIPITATING PATHOLOGY

- STEMI
- Toxic ingestion
- Hypoxia
- Hemorrhage

---



---



---



---



---



---




---



---

## MECHANISMS MITIGATED BY HYPOTHERMIA




---



---



---



---



---



---



---



---

## EVIDENCE

In 2005, International Liaison Committee on Resuscitation (ILCOR) and the American Heart Association (AHA) endorsed:

- Unconscious adult patients w/ ROSC after OHCA should be cooled to 32-34 degrees X12-24 hours with initial rhythm Vfib (Class IIa).
- Similar therapy may benefit patients w/ non-V-Fib or in-hospital arrest ( Class IIb).

---



---



---



---



---



---



---



---

## **EVIDENCE: TTM AT 33° VERSUS 36° AFTER CARDIAC ARREST**

- 950 unconscious adults out of hospital cardiac arrest presumed from cardiac origin
- Randomized to  $33^{\circ}\text{ C}$  vs  $36^{\circ}\text{ C}$  for 28 hours
- Followed by 72 hours of fever control ( $<37.5^{\circ}\text{ C}$ )

### **Result – targeted 33°C conferred no benefit**

- Mortality: 50% in 33°C group vs 48% in 36°C group
- At 180 days 54% died or had poor neuro status per Cerebral Performance Category in 33°C group vs 52% in 36°C group
- Using Modified Rankin scale both groups 52%

Nielsen, et al NEJM (2013)


## **EVIDENCE: 2015 AHA POST CARDIAC ARREST CARE GUIDELINES UPDATE**

- Comatose adult patients with ROSC after cardiac arrest should have TTM
- Maintain constant temperature between  $32^{\circ}\text{C} - 36^{\circ}\text{C}$
- After achieving target temperature, **maintain for at least 24 hours ( Class IIa )**
- Higher temperatures preferred in some patients where lower temperatures increase risk (e.g. bleeding)
- Lower temps preferred when patient has clinical finding worse at higher temps (e.g., seizures, cerebral edema)

AHA, 2015

## PROTOCOL EXAMPLE

## PHASES OF TTM



Scirica, Circulation (2018)

## INITIATION PHASE

### AIM: Rapidly cool

- Initiate within 6 hours of cardiac arrest
- Insert continuous temp monitoring device (PA/ Bladder/Esophageal)
- Insert A line/central line
- Labs/EKG prior to induction but don't delay
- Administer anti-shivering medications ( sedation/ analgesia/paralytic)

## TEMPERATURE MODULATING DEVICES

- Cold saline intravenous
- Ice packs- groin, axilla
- Surface cooling
  - Torso and leg wraps
- Esophageal Cooling Device
- Intravascular




---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---

## PHYSIOLOGIC EFFECTS OF HYPOTHERMIA

### Cardiovascular

- Initially HR, CO & BP followed by a HR, CO, BP
- **EKG Changes**
  - Prolonged PR interval
  - Widening QRS complex
  - Increased QT interval
  - Bradycardia
  - Osborne wave

### Hematologic

- Thrombocytopenia
- Impaired clotting cascade
- Impaired platelet function
- Decreased WBC Count

## PHYSIOLOGIC EFFECTS OF HYPOTHERMIA

### GI

- Impaired bowel function/motility
- Increased liver enzymes

### Endocrine

- Hyperglycemia
- Decreased insulin secretion

### Renal

- Diuresis
- Fluid/electrolyte imbalance

## PHYSIOLOGIC EFFECTS OF HYPOTHERMIA

### Systemic

- ↓ O<sub>2</sub> Consumption
- Left shift on the oxyhemoglobin curve
- ↓ CO<sub>2</sub> production
- ↑ Lactate levels

### Immune system

- ↓ Neutrophil and macrophage function
- ↑ risk of infection (wound infections and pneumonia)

---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---



---

## MAINTENANCE PHASE

**AIM:** Tightly control core temperature with minimal fluctuations

- Monitor VS continuously
- Minimize temperature fluctuations
- Assess for shivering hourly using Bedside Shivering Assessment Scale (BSAS)
- Assess water cooling device temperature
- Monitor labs- K, glucose

---



---



---



---



---



---



---



---

## REWARMING PHASE

**AIM:** Slow and controlled

- Begins 24 hours after goal temperature reached
- Avoid hyPERthermia
- Gradually rewarming at 0.25 degrees
- May consider rewarming at 0.1 degrees if concern with elevated intracranial pressure
- Maintain sedation/paralytic until temperature reached 36 degrees

Closely monitor for:

- Shivering
- Hypotension
- Hyperkalemia




---



---



---



---



---



---



---



---

## NORMOTHERMIA PHASE

- Avoid fevers
- Maintain normothermia for next 48-72 hours
- Monitor for shifts in electrolytes
- Monitor for s/s of infection ( ex. Increased WBC/ difficulty maintaining temp)
- **NO** prognostication before 72 hours of ROSC

---



---



---



---



---



---



---



---

## SHIVERING

Why prevent shivering?

Increases:

- O<sub>2</sub> consumption
- Energy expenditure
- CO<sub>2</sub> production
- Core temperature




---



---



---



---



---



---




---



---

## SHIVERING MECHANISM




---



---



---



---



---



---



---



---

## SHIVERING ASSESSMENT

Place hands over the patient's temples, masseters neck and upper thorax, pectoralis muscles to assess.

Goal: BSAS ≤ 1

### Score Definition

- 0 None: no shivering noted on palpation of the masseter, neck or chest wall
- 1 Mild: shivering localized to the neck and/or thorax only
- 2 Moderate: shivering involves gross movement of the upper extremities in addition to the neck and thorax
- 3 Severe: shivering involves gross movements of the trunk and upper and lower extremities

Badjatia, N, et al. 2008

---



---



---



---



---



---



---



---

## OTHER WAYS TO ASSESS SHIVERING

- Monitor trend indicators in cooling device



- EKG artifacts/irregularity



- Difficulty reaching /maintaining temperature goal

---



---



---



---



---



---



---

## SHIVERING PREVENTION

- Use skin counter warming
  - Bair Hugger
  - Hand/feet warmer
- Anti-shivering regimen
  - Buspar
  - Magnesium
  - Meperidine
  - Fentanyl
  - Dexmedetomidine
  - Propofol
  - Paralytics

---



---



---



---



---



---



---

## TAKE AWAY

- Time is brain
- Cool between 32-36 degrees
- After rewarming, maintain normothermia for 48-72 hours
- Prevent shivering
- No prognostication before 72 hours of ROSC

---



---



---



---



---



---



---

## REFERENCES

American Heart Association (2015). Highlights of the 2015 American Heart Association Guidelines Update for CPR and ECC

Badjatia, et al. (2008). Metabolic Impact of Shivering During Therapeutic Temperature Modulation. The Bedside Shivering Assessment Scale. *Stroke*. 39:3242-3247

Carwell, M. (2018). Targeted Temperature Management for Improved Outcomes. Are we there yet?. *Critical Care Nurse*. 11(2):102-108.

Nielsen, N. et al (2013). Targeted Temperature Management at 33° C versus 36 ° C after Cardiac Arrest. *New England Journal of Medicine*. 369:2197-2206

Polderman, 2009. Mechanisms of action, physiological effects, and complications of hypothermia. *Critical Care Medicine* 37(7).  
Doi: 10.1097.CCM.0b012e3181aa5241

Scirica, B. (2013). Therapeutic Hypothermia After Cardiac Arrest. *Circulation*. 127: 244-250.

